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Inﬁltration inhibitionThe protein tyrosine phosphatases (PTPs) SHP-1, SHP-2 and PTP1B are overexpressed early on during the devel-
opment of cerulein -induced acute pancreatitis (AP) in rats, and their levels can bemodulated by some species of
mitogen-activatedprotein kinases (MAPKs), the intracellular levels of cAMPandby general leukocyte inﬁltration,
the latter at least for SHP-2 and PTP1B. In this study we show that cerulein treatment activates extracellular
signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) but not p38 MAPK during the early phase
of cerulein-induced AP (2 h after the ﬁrst injection of cerulein). Therefore, by using the MAPK inhibitors
SP600125 (a speciﬁc JNK inhibitor) and PD98059 (a speciﬁc ERK inhibitor), we have unmasked the particular
MAPK that underlies the modulation of the expression levels of these PTPs. JNK would act by preventing SHP-1
protein expression from increasing beyond a certain level. ERK 1/2 was the main MAPK involved in the increase
in SHP-2 protein expression due to cerulein. JNK negatively modulated the SH2-domain containing PTPs. Both
MAPKs played a role in the increase in PTP1B protein expression due to cerulein. Finally, by using the white
blood cell inhibitors vinblastine sulfate, gadolinium chloride and FK506 (tacrolimus), we show that the macro-
phage activity or T-lymphocytes does not modulate the expression of any of the PTPs, although neutrophil inﬁl-
tration was found to be a regulator of SHP-2 and PTP1B protein expression due to cerulein.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
During the course of acute pancreatitis (AP), different pathophysio-
logical responses occur in intrapancreatic regions, including the activa-
tion of pancreatic enzymes and inﬂammatory mediators, the formation
of free radicals and changes in blood ﬂow. Some of these factors may
also affect peripancreatic tissue or even distant organs. Nevertheless,
the molecular mechanisms involved in the development of AP remain
incompletely understood, especially the early acinar events, although
these signaling mechanisms would determine the development of
pancreatitis [1].
One of the animal models of the edematous form of AP is that in-
duced by cerulein (Cer). Under the conditions used here the manifesta-
tions of pancreatitis include hyperamylasemia, increased pancreatic
weight and pancreatic cell size, edema acinar cell damage, and inﬂam-
matory cell inﬁltration [2–5]. The intracellular mechanisms by which
Cer regulate pancreatic acinar function are very complex. Cermodulatesca y Biología Molecular, Ediﬁcio
s/n, 37007 Salamanca, Spain.
ights reserved.tyrosine phosphorylation [6,7], a central regulatorymechanismofmany
cell functions, including the maintenance of cell adhesion complexes
[8], that are known to be dissociated in pancreatitis [9,10]. Cer-
induced AP also activates the mitogen-activated protein kinase
(MAPK) cascade, which requires the phosphorylation of both tyrosine
and threonine residues [11,12]. The adenosine A1-receptor pathway
[13], which decreases intracellular cAMP levels, also becomes activated
in AP, and increases in intracellular cAMP are known to enhance
secretagogue-sensitive zymogen activation. Recently, we have reported
that the expression of three different protein tyrosine phosphatases
(PTP)—the SH2-domain containing PTPs SHP-1 and SHP-2, as well as
PTP1B, is increased at both the gene and protein levels early on in the
development of Cer-induced AP [14,15]. It is known that in AP PTPs
play roles in the regulation of exocytotic processes in exocrine pancreat-
ic acinar cells [16] and in different inﬂammatory diseases. Additionally,
they may become inactivated by reactive oxygen species or secondary
products of oxidation [17] that may form during the development
of AP [18], thus affecting protein tyrosine phosphorylation levels
(although such a redox-mediated activity modulation has never been
conﬁrmed in AP). SHP-1 has been implicated in the Jak–Stat and
MAPK pathways [19]. SHP-2 is involved in at least the Ras–Raf–MAPK,
Jak–Stat, PI3 kinase and NF-κB pathways [20]. PTP1B is a key controller
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bers of the Janus kinases/signal transducers and activators of transcrip-
tion (JAK/STAT) pathway [21]. All the above PTP signaling pathways
have been implicated in the development of AP.We have also previous-
ly reported that the increases observed in the protein levels of the three
PTPs during the early phase of Cer-induced AP may somehow be mod-
ulated by inhibition of MAPK pathways [14,15], although the speciﬁc
MAPK implicated in suchmodulation is unknown. Moreover, leukocyte
inﬁltration seems to affect at least SHP-2 and PTP1B expression in some
way [14,15]. It has been recently conﬁrmed that the inﬁltration of in-
ﬂammatory cells into the pancreas is an early, central and trigger
event in AP [22]. This inﬁltration causes local and systemic injury in
the disease. Not only neutrophils, which are key players in acute inﬂam-
matory diseases, but also inﬂammatory monocytes and macrophages,
and even lymphocytes, are involved in the development of acute exper-
imental pancreatitis [23]. In this regard, the attenuation of the proin-
ﬂammatory immune response by speciﬁcally targeting neutrophils,
monocytes or lymphocytes improves the early course of several models
of experimental pancreatitis [24–26].
In light of the above, here we unmask the particular MAPK that un-
derlies modulation of the expression levels of SHP-1, SHP-2 and PTP1B
in the early phase of Cer-induced AP development, by using the MAPK
inhibitors SP600125 and PD98059. For comparison, the effect of the in-
crease of cAMP (by inhibiting type IV phosphodiesterase) in the expres-
sion levels of the PTPs was also analyzed. Finally, we also studied the
inﬂuence of different inﬂammatory cells in the changes in PTP expres-
sion by using vinblastine sulfate, which elicits a neutropenic state,
gadolinium chloride (GdCl3), which inactivates macrophage activity,
and FK506 (tacrolimus) an immunomodulatory drug that preferentially
decreases T-lymphocyte proliferation.
2. Materials and methods
2.1. Reagents
Bovine serum albumin (BSA), cerulein (Cer), dithiothreitol (DTT),
FK506, gadolinium chloride (GdCl3), phenylmethylsulfonyl ﬂuoride
(PMSF), PD98059, Protein Inhibitor Cocktail, rolipram, soybean trypsin
inhibitor, SP600125, and vinblastine sulfate were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Polyvinylidene diﬂuoride
(PVDF) membranes were obtained from Amersham Biosciences,
Spain. Monoclonal antibodies anti-PTP-1 (D-11), anti-p-ERK (E-4) and
p38α/β (A-12), and polyclonal antibodies anti-ERK 1 (K-23) and JNK1
(FL) were obtained from Santa Cruz Biotechnology, Inc., CA, USA.
Monoclonal antibody anti-PTP-2 was obtained from BD Biosci-
ences Pharmingen, San Diego, CA, USA. Monoclonal antibody
anti-PTP1B (ab52650) was obtained from Abcam, Cambridge, UK.
Polyclonal antibodies anti-p-SAPK/JNK (Thr183/Tyr185) and anti-p-
p38 (Thr180/Tyr182) were acquired from Cell Signalling Technology
(Danvers, MA, USA). Monoclonal antibody anti-GAPDH was acquired
from Ambion, Inc., Applied Biosystems, Madrid, Spain. Biotinylated
anti-rabbit immunogammaglobulin and avidin–biotin–peroxidase
complex were purchased from Vector (Burlingame, CA, USA). The
Myeloperoxidase (MPO) Peroxidation Assay Kit was purchased from
Cayman Chemical Company, MI, USA. Aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) enzymatic assay kits were
obtained from RAL, Barcelona, Spain.
2.2. Animals
YoungmaleWistar ratsweighing 250–280 gwere used. The animals
were housed in roomsmaintained at 22 ± 1 °C using a 12-h light/dark
cycle and they were fasted for 24 h before experiments, with free
access to water. Care was provided in accordance with the proce-
dures outlined in European Community guidelines on ethicalanimal research (86/609/EEC), and protocols were approved by
the Animal Care Committee of the University of Salamanca.2.3. Induction of AP and preparation of samples
The early and intermediate phases of AP were induced as described
previously [14,15]. Brieﬂy, rats received 2 (early phase) or 4 (intermedi-
ate phase) s.c. injections of 20 μg Cer/kg body weight or its vehicle
(0.9% NaCl) at hourly intervals. At 2 or 4 h after the ﬁrst injection, the
animals were anesthetized with sodium pentobarbital (100 mg/kg),
blood sampleswere taken from the tail and by cardiac puncture and an-
imalswere then killed. The pancreata,whichwere used immediately for
experiments, were rapidly dissected out from the surrounding fat tissue
and lymph nodes, and their wetweights rapidlymeasured. A small por-
tion of the tissue was used for histological studies [14]. The remaining
parts of the pancreata were homogenized individually with a Potter
Elvehjem device in 4 ml of homogenization buffer (3 mM imidazole
buffer, pH 7.4 containing 0.25 M sucrose, 1 mM EDTA, 1 mM PMSF,
100 μg/ml trypsin inhibitor, 100 μM TPCK and TLCK, 2 μg/ml Protease
Inhibitor Cocktail, 1 mMNaF and 1 mMNa3VO4). Homogenization buff-
er was added to reach a ratio of 10 volumes (w/v) and a postnuclear
homogenate of each pancreas was obtained as described before [27].
Serum samples were stored at −80 °C until amylase determination
with a Gernon Star Modular Analyzer, using a RAL assay kit, as reported
previously [14]. Protein concentrations were assayed by the method of
Bradford [28] using BSA as standard. Special care was taken with this
assay in order to minimize deviations in the amount of proteins loaded
in each lane of the SDS-PAGE gels. Quality control of the assays was en-
sured by repeating them at least three timeswith ﬁve different volumes
of three-to-ﬁve different sample dilutions.2.4. Light microscopy and immunohistochemistry
Parafﬁn-embedded tissue sections (8- to 10-μm thick) were stained
with hematoxylin and eosin (H&E staining), as indicated previously
[15], or subjected to immunostaining using the streptavidin peroxidase
technique. For the latter, the sections were incubated for 30 min at
room temperature in phosphate-buffered saline (0.15 M, pH 7.2) con-
taining 1% normal horse serum and 0.3% Triton X-100 (buffer A) before
overnight incubation at 4 °Cwith anti-PTP1B polyclonal antibody dilut-
ed 1:50. Bound antibody was detected with a biotinylated anti-rabbit
immunoglobulin (Ig) G (1 h, 1:200 dilution in buffer A at room temper-
ature) and avidin–biotin–peroxidase complex (1 h, 1:100 dilution in
buffer A at room temperature). The tissue-bound peroxidase was
developed with H2O2, using 3,3-diaminobenzidine as chromogen.
To ensure the speciﬁcity of the primary antibody, we incubated sec-
tions in either the absence of the primary antibody or with a non-
immunized rabbit IgG antibody. In these cases, no immunostaining
was detected.2.5. Inhibition of MAPKs by SP600125 and PD98059 or of type IV phospho-
diesterase by rolipram in Cer-induced AP
Rats received intraperitoneal (i.p.) injections of SP600125 (15 mg/kg),
PD98059 (5 mg/kg), rolipram (5 mg/kg) or their vehicles [1 ml/kg of a
10% DMSO/NaCl solution (SP600125 and rolipram) or 1% Pluronic F-68
in DMSO (PD98059)] both 2 h before and 30 min after (SP600125)
[12], 1 h before (PD98059) [29], or 30 min before and 30 min after
(rolipram) [30] the ﬁrst Cer injection. At 2 h, 1 h or 30 min after the
ﬁrst injection of SP600125, PD98059 or rolipram, respectively, the rats
were injected subcutaneously with Cer (20 μg Cer/kg) or its vehicle
(0.9% NaCl) at hourly intervals. The animals were sacriﬁced 2 h after the
ﬁrst Cer injection (early phase of Cer-induced AP).
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Vinblastine sulfate was dissolved in sterile 10 mM sodium phos-
phate buffer, 147 mMNaCl, and 2.7 mMKCl (pH 7.4) and administered
to rats intravenously (i.v.) at a dose of 0.75 mg/kg on day 1, as previous-
ly described [31]. At this dose, the animals become neutropenic be-
tween days 4 and 6 [31]. On day 5 after vinblastine sulfate or saline
administration, the animals were treated with 4 doses of Cer (20 μg
Cer/kg, administered at hourly intervals) to induce AP. FK506 and
GdCl3 were dissolved in 1 ml of the same buffer as the vinblastine sul-
fate. FK506 was administered to rats subcutaneously (0.3 mg/kg body
weight) 48 h before the induction of the pancreatitis in 24 h intervals
[26]. GdCl3 (1 mg/100 g of body weight) was injected into the rat tail
vein 12 h and 1 h before the start of Cer or saline administration [32].
2.7. Whole and differential white blood cell (WBC) count
Whole WBC and neutrophils were counted from cardiac puncture
blood samples by ﬂow cytometry using a Sysmex XT-2000i automated
hematology analyzer. Differential WBC counts were done using periph-
eral blood smears made from drops of blood from the tail vein. The
slides were stained using the May–Grünwald–Giemsa method. One
hundred cells/blood sample were counted to obtain the leukocyte
formula.
2.8. Myeloperoxidase (MPO) assay
MPO activity was detected in the pancreatic postnuclear homoge-
nates immediately after their collection using theMyeloperoxidase Per-
oxidation Assay Kit and following the manufacturer's instructions.
2.9. Serum AST and ALT determination
Serum levels of AST and ALT were determinedwith enzymatic assay
kits, using a Gernon Star Modular Bio-Chemical analyzer and following
the manufacturer's instructions.
2.10. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting
PTPs were analyzed by SDS-PAGE using 10% gels [33]. The proteins
present in the gels were transferred to PVDFmembranes. After blocking
non-speciﬁc binding with 5% non-fat dry milk (dissolved in buffer
10 mM Tris–HCl, 100 mM NaCl, 0.1% Tween 20, pH 7.5), Western
blots were probed with anti-SHP-1, anti-SHP-2 and anti-PTP1B mono-
clonal antibodies, or anti-GAPDH polyclonal antibodies, diluted 1:150,
1:2500, 1:1000 or 1:40,000, respectively, in the blocking solution.
Blots were visualized by chemiluminescence. Analyses of the spots on
all the blots were performed as described previously [34]. The densities
corresponding to the different PTP bands in the different treatments
were normalized to the GAPDH band densities (used as a loading con-
trol). The images shown in the ﬁgures are from blots whose ﬁlms
were exposed for optimal reproduction rather than for the linearity of
band densities.
2.11. ERK, JNK and p38 phosphorylation
Activation ofMAP kinaseswas assessed as previously described [35].
ERK, JNK and p38 kinase activationwas evaluatedwith use of antibodies
that recognize dually phosphorylated (Thr/Tyr) MAP kinase, diluted
1:200, 1:1000 and 1:1000, respectively. The blots were stripped and
then normalized to total ERK, JNK or p38 kinases with the use of anti-
bodies that recognize theMAP kinases regardless of its phosphorylation
state.2.12. Statistical analysis
Data are expressed as means ± SD. They were analyzed (version
19.0 of the SPSS program for MS Windows, SPSS, Chicago, Ill) using
the non-parametric Mann–Whitney U test. Statistical signiﬁcance was
considered for a p value b0.05.
3. Results
Wehave previously divided the development of our animalmodel of
AP into the early, intermediate and later (2, 4 and 9 h after the ﬁrst in-
jection of Cer) phases of AP [14,15]. In this work, serum amylase deter-
mination and histological assessment were used for monitoring the
establishment of initial and intermediate phases of clinically relevant
relatively mild edematous pancreatitis. Similarly to our previously re-
ported data [15,36], as early as 2 h after the ﬁrst injection of Cer pancre-
atic acinar cell disruption and some lymphocyte inﬁltration were
observed. A higher degree of leukocyte inﬁltration, higher numbers of
unstructured acini and some neutrophils were detected during the in-
termediate phase of Cer-induced AP (Supporting Information 1).
3.1. Effect of MAPK inhibitors and rolipram on PTP expression and ERK 1/2
and JNK activation
Figs. 1 and 2 show the expression levels of the very similar SH2-
domain containing PTPs SHP-1 and SHP-2, and PTP1B, respectively.
They also illustrate the effect on such levels of two different MAPK in-
hibitors—SP600125 and PD98059 (Fig. 1)—and rolipram, an inhibitor
of type IV phosphodiesterase (Fig. 2), during the early phase of Cer-
induced AP. In all groups of rats, PTP expression levels (Western blots
in whole postnuclear pancreatic homogenates) were quantiﬁed
(graphics) in two different ways: (1) for an equal amount of proteins
(open bars), (2) with respect to the total amount of proteins in the
whole pancreas (shaded bars). It is well known that pancreatitis is asso-
ciated with the neutrophil inﬁltration and cell death that differentiate
the cell composition of the pancreata of the groups of rats. Accordingly,
we considered that a better interpretation of the results would require
the expression of the data with respect to the total amount of proteins
in the pancreas. We have previously reported an increase in the protein
levels of the three PTPs during the early phase of Cer-induced AP that
may in someway be modulated by MAPK inhibition and the intracellu-
lar cAMP pathway [14,15], although the speciﬁc MAPK implicated in
such modulation is unknown. It is known that such signaling pathways
play essential roles in the pathogenesis of AP, in part due to an amelio-
ration of the severity of Cer-induced AP after inhibition of JNK and ERK
1/2 kinases or after increasing cAMP levels in neutrophils [12,30]. In
Fig. 1 it can be observed that rather than reducing the increase in the ex-
pression of SH2-domain containing PTPs, SP600125 pretreatment sig-
niﬁcantly increased the expression of both SHP-1 and SHP-2 after Cer
administration. With respect to PTP1B, SP600125 pretreatment mostly
reduced the increase in its expression after Cer treatment. In Fig. 1 it is
also shown that, by contrast, PD98059 pretreatment did not affect the
increase in expression of SHP-1 and was able to reduce signiﬁcantly
the increase in SHP-2 expression observed after Cer administration. As
in the case of SP600125, PD98059 pretreatment mostly reduced the in-
crease in PTP1B expression after the Cer treatment. In Fig. 2 it can be ob-
served that in comparison with the non-pretreated animals SHP-1
protein expression due to Cer was not modiﬁed and SHP-2 protein ex-
pression due to Cer was signiﬁcantly suppressed in the pancreata ob-
tained from Cer-injected rats pretreated with rolipram. With respect
to PTP1B, rolipram pretreatment mostly reduced the increase in the
PTP protein expression due to Cer.
Once it had been conﬁrmed that the increases in the expression
levels of the PTPs due to Cer during the early phase of AP were
affected by the signaling pathways studied, we analyzed the activation
of ERK 1/2 and JNK in the different groups of rats. Fig. 3 shows that
Fig. 1. Effect of MAPK inhibitor pretreatments on SHP-1, SHP-2 and PTP1B protein expression in the early phase of Cer-induced AP. Rats were pretreated with SP600125, PD98059 or its
vehicle as indicated in the “Materials and methods” section. Then, the animals were injected subcutaneously with either Cer or its vehicle [20 mg/kg or saline (0.9% NaCl, Sal) in two in-
jections at hourly intervals, respectively]. Quantiﬁcation (graphics, values given as SHP1/GAPDH, SHP-2/GAPDH and PTP1B/GAPDH ratios, and considering both controls: Sal + vehicle
and Sal + inhibitor as 1) of expression (Western blots in whole postnuclear pancreatic homogenates— a representative is shown —where the 2 animals pretreated with the inhibitors
are representative of the higher and lower levels of the standard deviation of the experiment) was carried out both per mg of proteins (□) and considering the whole pancreas (■). Each
lane in the blots contained 25 μg of proteins. Data are means ± S.D. of 3 experiments with 3 rats per group in each experiment.
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and JNK. Although SP600125 and PD98059 are respectively speciﬁc
JNK and ERK 1/2 inhibitors, their use in animals may lead tomixed inhi-
bitions of both MAPKs [12]. Accordingly, it was necessary to conﬁrm
whether under the conditions used in this study they led to a selective
inhibition of one of theMAPKs. As shown in Fig. 3, in vivo both inhibitors
maintained their selective inhibition. Thus, SP600125 and PD98059pre-
treatments led to speciﬁc reductions of JNK and ERK1/2 activation, re-
spectively. Although to our knowledge it has never been reported that
SP600125 or PD98059 might inhibit p38 MAPK, we also analyzed the
activation of this latter kinase in the different groups of rats. As shown
in Supporting Information 2, during the early phase of Cer-induced AP
the phosphorylation of p38 was not signiﬁcantly affected, and neither
was it affected after SP600125 or PD98059 pretreatments. The lack of
response of p38 to Cer is consistent with previously reported data in a
similar rat model of AP [29]. Since the phosphorylation of ERK, JNK
and p38 determines the activity of MAPK signaling, these data supportthe notion that, as expected, p38 does not play a role in the modulation
of PTP expression after ERK or JNK inhibition. Therefore, such modula-
tion must be carried by one or both of the two latter MAPKs. With re-
spect to rolipram pretreatment, the activation of the MAPKs did not
change with respect to the increase detected after Cer treatment.
3.2. Effect of white blood cell inhibitors on blood cell counts
The development of inﬂammation and cell death in pancreatitis is
somehow inﬂuenced by neutrophil inﬁltration. Additionally, the pan-
creas probably contains an unknown proportion of resident macro-
phages, whose activity, as well as that of liver Kupffer cells should be
blocked by GdCl3 [23]. Nevertheless, the effects of GdCl3 on resident
macrophages in the pancreas remain unknown. It is also known that
lymphocytes are involved in AP since the calcineurin antagonist FK506
reduces the severity of the disease [23]. In some cases, rats were ren-
dered neutropenic with vinblastine sulfate before treatment with
Fig. 2. Effect of PDE4 inhibitor pretreatment on SHP-1, SHP-2 and PTP1B protein expres-
sion in the early phase of Cer-inducedAP. Ratswere pretreatedwith rolipramor its vehicle
as indicated in the “Materials and methods” section. Then, the animals were injected sub-
cutaneouslywith either Cer or its vehicle [20 mg/kg or saline (0.9%NaCl, Sal) in two injec-
tions at hourly intervals, respectively]. Quantiﬁcation of expression was carried out as
indicated in the legend of Fig. 1. Each lane in the blots contained 25 μg of proteins. Data
are means ± S.D. of 3 experiments with 3 rats per group in each experiment.
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scribed by us and others [14,15,31]. A count of the cells in the blood of
the rats used in our experiments is shown in Supporting Information
3. As expected, a differential leukocyte count in the blood revealed a sig-
niﬁcant decrease in the percentage of neutrophils only in the groups
pretreated with vinblastine sulfate (Supporting Information 4).
3.3. Effect of MAPK inhibitors, rolipram and white blood cell inhibitors on
serum amylase, edema and pancreatic MPO levels
Figs. 4 and 5 illustrate the levels of serum amylase in all groups.
PD98059 was not able to reduce, SP600125 showed a tendency
(although not signiﬁcant) to reduce, and rolipram signiﬁcantly
reduced the serum amylase activity observed in the animals given Cer
alone (2 h after the ﬁrst injection of Cer). Regarding white blood cellinhibitors, we decided to study the intermediate phase of AP (4 h) be-
cause it has been reported that inﬂammatory cell inﬁltration has already
taken place at this time [37]. In this case, only the group of rats
pretreatedwith vinblastine sulfate and then treatedwith GdCl3 showed
a signiﬁcant reduction in serum amylase activity with respect to the an-
imals given Cer alone. Therefore, the lack of effect of GdCl3 itself on
serum amylase activity differs from previously reported data [32].
Supporting Information 5 shows that Cer treatments also resulted in
signiﬁcant organ edema, as evidenced by the increased pancreatic wet
weight. Regarding the MAPK inhibitors, pretreatments with SP600125
and PD98059 were associated with an 80 and 57% reduction in the
Cer-induced edema, respectively, which supports the notion of an
early protective effect of MAPK inhibition on intrapancreatic damage.
By contrast, rolipram pretreatment did not reduce the extent of the
edema during the early phase of Cer-induced AP, although such a pro-
tective effect has been reported in fully developed Cer-induced AP
[30]. This is probably due to the fact that neutrophil inﬁltration is still
low during this early phase (2 h after the ﬁrst Cer injection).
Leukocyte accumulation in the pancreas was investigated by mea-
suring MPO activity (4 h after the ﬁrst injection of Cer). In Fig. 5 it
may be seen that while Cer treatment caused leukocyte accumulation
in the pancreas, the groups of rats that were pretreatedwith vinblastine
sulfate had blunted pancreatic MPO levels. Unlike previously reported
data [32], GdCl3 also signiﬁcantly decreased pancreatic MPO activity, al-
though the decrease was much more pronounced in the group of rats
pretreated with vinblastine sulfate.
3.4. Effect of white blood cell inhibitors on hepatic functions
No signiﬁcant changes were found on the hepatic functions of
GdCl3- or FK506-treated animals measured as serum values of ALT
and AST (Supporting Information 6).
3.5. Effect of white blood cell inhibitors on PTP expression
We have previously reported that the early increase in the expres-
sion of both SHP-1 and PTP1B (2 h after the ﬁrst injection of Cer) per-
sists during the intermediate phase of AP (4 h after the ﬁrst injection
of Cer), although to a lower extent. By contrast, SHP-2 expression falls
to levels similar to those of the controls from 4 h onwards [14,15].
Fig. 6 shows that GdCl3 alone did not signiﬁcantly affect the changes
in protein expression of any of the PTPs after Cer treatment. Neverthe-
less, the depletion of neutrophils in the rats (rats pretreated with vin-
blastine sulfate) speciﬁcally increased SHP-2 protein expression
during the intermediate phase of AP to a signiﬁcant extent. Also,
FK506 alone did not signiﬁcantly affect the changes in protein expres-
sion of any of the PTPs after Cer treatment. In this case, pretreatment
with vinblastine sulfate was speciﬁcally associated with the decrease
in PTP1B expression to levels similar to those of the controls. Since
this might indicate that the increase in PTP1B expression due to Cer
could occur mainly in leukocytes associated with the inﬂammatory in-
ﬁltrate of the pancreas rather than with the acinar cells, immunohisto-
chemical analyses were performed. Supporting Information 7 shows
the increase in PTP1B immunoreactivity during the early and intermedi-
ate phases of Cer-induced AP; this can be mainly ascribed to the acinar
cells and not to the inﬁltration. The data support a kind of crosstalk be-
tween inﬁltration and acinar cells that needs to be addressed in the
future.
4. Discussion
It seems clear that one of the important factors in the development
of APmust be the differential change in gene and/or protein expressions
in the pancreas during the initial phase of the disease [1]. Such changes
might transfer the early activated signaling pathways in pancreatic aci-
nar cells towards ﬁnal responses even in extrapancreatic tissues. The
Fig. 3.MAPK activation state in control (Sal) or pancreatitic (Cer, early phase of Cer-induced AP) rats pretreated or non-pretreated with MAPKs or PDE4 inhibitors. Activation of signaling
cascades was analyzed by immunoblotting with antibodies that recognized the phosphorylated/active forms of ERK and JNK. The samemembranes were stripped and reprobed to check
the total levels of these proteins. The levels of the phosphorylated/active formswere quantiﬁed and normalizedwith respect to the total levels of these proteins (graphics). Each lane in the
blots contained 20 μg of proteins. Data are means ± S.D. of 3 experiments with 3 rats per group in each experiment.
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diating role during the early phase (ﬁrst 1–1.5 h) of AP [12,31,38], and
might regulate transcription factors (TFs) induced early on during the
onset of AP [1], as well as protein translation [39]. Regarding this, we
have previously reported an increase in SHP-1, SHP-2 and PTP1B in
the pancreas at the level of both protein and mRNA as an early event
during the development of Cer-induced AP [14,15]. The fact that out of
this three PTPs SHP-2 also increased its protein expression in in vivo
models of AP brought about by sodium-taurocholate duct infusion and
in bile-pancreatic duct obstruction highlights the probable generalimportance of this PTP in AP [14,15]. We have also reported that the
ERK 1/2 and/or JNK kinases, cAMP levels, and general inﬁltration of
the pancreas modulate the protein expression of all or some of the
PTPs in the early phase of Cer-induced AP [14,15]. Nevertheless, the spe-
ciﬁc MAPK involved in each case, as well as the inﬂuence of different
types of leukocytes is unknown.
The study of the MAPK involved in PTP protein modulation was ac-
complished using different inhibitors: SP600125, a JNK inhibitor, and
PD98059, an ERK 1/2 inhibitor. It should be noted that although these
molecules are speciﬁc inhibitors of one type of MAPK, their use in
Fig. 4. Effect of MAPKs and PDE4 inhibitor pretreatments on serum amylase activity in the
early phase of Cer-induced AP. Rats were pretreatedwith SP600125, PD98059 or rolipram
as indicated in the “Materials and methods” section. Then, the animals were injected sub-
cutaneouslywith either Cer or its vehicle [20 mg/kg or saline (0.9%NaCl, Sal) in two injec-
tions at hourly intervals, respectively]. Data aremeans ± S.D. of 3 experimentswith 3 rats
per group in each experiment.
Fig. 5. Effect of white blood cell inhibitor pretreatments on serum amylase and pancreatic
GdCl3, FK506 or their vehicles as indicated in the “Materials and methods” section. Then
or saline (0.9% NaCl, Sal) in four injections at hourly intervals, respectively]. One group o
fore pretreatments with GdCl3 or FK506 as indicated in the “Materials and methods
experiment.
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analysis of the activation state of the kinases after treatmentwith the in-
hibitors was necessary to clearly ascribe the modulation of a particular
PTP to a speciﬁc MAPK. Such an analysis was also performed for
rolipram, a speciﬁc strong inhibitor of type IV phosphodiesterase.
Under the conditions used in this work, SP600125 and PD98059 respec-
tively almost completely inhibited the activation of Cer-induced pancre-
atic JNK and ERK 1/2, the only two MAPKs that became activated after
Cer treatment. Rolipram pretreatment did not affect the MAPK activa-
tion state. These results led us to conclude that in the early phase of
Cer-induced AP: (i) JNK would be acting by preventing SHP-1 protein
expression from increasing beyond a certain level, because the further
increase in SHP-1 expression with respect to that observed after Cer
treatment occurred only after SP600125, but not after PD98059 pre-
treatment. Moreover, ERK 1/2 does not seem to be involved in the in-
crease in SHP-1 protein expression due to Cer. (ii) ERK 1/2 was the
main MAPK involved in the increase in SHP-2 protein expression due
to Cer, because such an effect was blunted only after PD98059 pretreat-
ment. For this PTP, JNK seems to play a role similar to the one describe
for SHP-1. In light of the above, JNK seems to negatively modulate the
SH2-domain containing PTPs. (iii) Both MAPKs seem to play a coordi-
nated role in the increase in PTP1B protein expression due to Cer, be-
cause such an effect was equally blunted after SP600125 or PD98059
pretreatments. These roles of JNK are interesting also in relation to our
recent observation that STRAP, an inhibitor of transforming growth
factor β (TGF-β), that acts as a negative regulator of the apoptosis
signal-regulating kinase 1 (ASK-1)-mediated JNK signaling cascade, is
overexpressed during the early phase of Cer-induced AP [35]. (iv) The
experimentswith rolipramwere done for comparison andas an internal
quality control of our results. The results concerning SHP-1 and PTP1B
coincided with those previously reported by us [14,15]. The SHP-2 re-
sults were partly different because, here, the suppression of the increase
in SHP-2 protein expression due to Cer in rolipram-pretreated rats, al-
though signiﬁcant, was much lower than in our previous experiments
[14]. It is known that MAPKs [12] and the increases in intracellularMPO levels in the intermediate phase of Cer-induced AP. Rats were pretreated with
, the animals were injected subcutaneously with either Cer or its vehicle [20 mg/kg
f rats (Vin) was given 0.75 mg/kg i.v. vinblastine sulfate to induce neutropenia be-
” section. Data are means ± S.D. of 3 experiments with 3 rats per group in each
Fig. 6. Effect of white blood cell inhibitor pretreatments on SHP-1, SHP-2 and PTP1B protein expression in the intermediate phase of Cer-induced AP. Rats were pretreatedwith vinblastine
sulfate, GdCl3, FK506 or their vehicles as indicated in the legend of Fig. 5. Quantiﬁcation (graphics, values given as SHP1/GAPDH, SHP-2/GAPDH and PTP1B/GAPDH ratios) of expression
(Western blots inwhole postnuclear pancreatic homogenates— a representative is shown)was carried out both permg of proteins (□) and considering thewhole pancreas (■). Each lane
in the blots contained 25 μg of proteins. Data are means ± S.D. of 3 experiments with 3 rats per group in each experiment.
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matory cytokines, such as TNF-α, that prime cell inﬁltration in the pan-
creas, respectively. Also, the identiﬁcation of a pool of a soluble adenylyl
cyclase associated with isolated nuclei in unstimulated pancreatic aci-
nar cells, raises the possibility of the implication of this cyclase, and of
a compartmentalized cAMP signal, in transcriptional responses [41].
It is known that neutrophil depletion due to an antineutrophil serum
or vinblastine sulfate administration reduces the severity of AP because
neutrophil inﬁltration into tissues plays an important role in its devel-
opment. However, the protection remains partial, perhaps reﬂecting
the presence of local pancreatic macrophages [32]. GdCl3, a compound
that is not toxic at the dose use in this work [23,42], has been employed
to inactivate Kupffer cells [32], the residentmacrophages in the liver, al-
though it is also possible that gadoliniummight have effects on resident
macrophages in the pancreas [23]. Kupffer cells are regarded as the pre-
dominant source of inﬂammatory cytokines producing systemic injuryin AP [43]. Also, activated lymphocytes, especially T lymphocytes, prob-
ably play a role in the development of AP [23], although a less important
one than that of neutrophils. Thus, in Cer-induced AP inmice it has been
reported that the CD4+ T helper subset is amediator of local tissue inju-
ry [44]. FK506, a drugwithout signiﬁcant adverse effects on the exocrine
pancreas, exerts its action on T-helper lymphocytes after binding to in-
tracellular immunophilins, thus inhibiting calcineurin phosphatase [45].
This phosphatase is involved in the activation of the transcription nucle-
ar factor of activated T cells that modulates the expression of cytokine
genes. Nevertheless, the inﬂuence of FK506 in AP is not well understood
[46,47] because both attenuation and no changes in intrapancreatic
damage have been reported, depending on the animal model used for
the induction of pancreatitis [47,48].
Our results indicate that GdCl3 by itself did not modulate the
expression of any of the PTP due to Cer. The positive modulation of
SHP-2 protein expression observed in the whole pancreas of rats
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the neutrophil depletion due to vinblastine administration, because we
have previously demonstrated that such an effect is already produced in
rats pretreated onlywith vinblastine [14]. Accordingly, no effect of cyto-
kines produced by the resident macrophages of the liver, and probably
also by the resident macrophages of the pancreas, seems to be involved
in the increase in PTP protein expression due to Cer. With respect to
FK506, similar conclusions to those observed for GdCl3 can be drawn
for the SH2-domain containing phosphatases: (i) FK506 alone did not
modulate their expression due to Cer, and (ii) the changes observed in
SHP-2 protein expression in the Vin + FK506 + Cer group of rats
should be ascribed to the neutrophil depletion due to vinblastine [14].
Regarding PTP1B, the increase in the expression of PTP1B protein due
to Cer was blunted in the Vin + FK506 + Cer group of rats. This effect
should also be ascribed to the neutropenic state, because it was not ob-
served in the FK506 + Cer group (thiswork)whereas it was in our pre-
vious work using rats pretreated only with vinblastine [15]. These data
indicate a role of neutrophil inﬁltration as a regulator of PTP1B protein
expression and are in good agreement with those for rolipram, because
type 4 phosphodiesterase is abundantly expressed in neutrophils. Ac-
cordingly, rolipram will target at least neutrophils, probably exerting
anti-inﬂammatory effects through the inhibition of diverse leukocyte
functions such as the production/secretion of proinﬂammatory cyto-
kines, as indicated above. The data are also in accordance with previous
work reporting that rolipram suppressed neutrophil inﬁltration in the
pancreas due to Cer [13].
Concerning serum amylase activity, the lack of an effect of MAPK in-
hibitors and rolipramon its increase due to Cer is coincidentwith previ-
ously reported data [14,15]. By contrast, in fully developed Cer-induced
AP it has been reported that SP600125 signiﬁcantly reduces the increase
in serum amylase activity due to Cer [12]. Taken together, the data sup-
port the notion that the reduction in amylase activity afterMAPK inhibi-
tion would not occur during the early phase of AP but later in its
development, as indicated elsewhere [14,15]. GdCl3 and FK506 alone
did not decrease serum amylase activity. The lack of effect of FK506 re-
garding the decrease in serum amylase activity due to Cer has been also
reported in a rat model of fully developed Cer-induced AP [26]. By con-
trast, in a micemodel of fully developed Cer-induced AP the prevention
of Kupffer cell activation by GdCl3 signiﬁcantly reduced the increase in
serum amylase activity due to Cer [32]. Accordingly, a reduction in
such activity would probably also occur later in the development of
AP. Neutrophil inﬁltration (assessed by MPO activity) was already ob-
served during the intermediate phase of Cer-induced AP, as previously
reported [14,15]. Since GdCl3 is speciﬁcally taken up by Kupffer cells
[32], the fact that GdCl3 alone reduced MPO activity probably reﬂects
the presence of local pancreatic macrophages. MPO activity was
completely reduced to the control level when GdCl3 treatment was
associated with a neutropenic state. The fact that FK506 treatment
also associated to a neutropenic state reduced MPO activity almost
completely, although not totally, further supports the notion that
the residual MPO activity might reﬂect the existence of macro-
phages in the pancreas.
In sum, here we unmask the particular MAPK that underlies the
modulation of the expression levels of SHP-1, SHP-2 and PTP1B in the
early phase of Cer-induced AP development. JNK did not allow SHP-1
protein expression to increase beyond a certain level. ERK 1/2 was
the main MAPK involved in the increase in SHP-2 protein expression
due to Cer, but was not involved in the increase in SHP-1 protein ex-
pression. JNK negatively modulated the SH2-domain containing
PTPs. Both MAPKs played a coordinated role in the increase in
PTP1B protein expression due to Cer. Finally, neither macrophage ac-
tivity nor T-lymphocytes modulated the expression of any of the
PTPs, although neutrophil inﬁltration was a regulator of SHP-2 and
PTP1B protein expression due to Cer.
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